As a growing biotech, Abera Bioscience requires regulatory partners who understand both the scientific and the business challenges of vaccine development. They have chosen RegSmart as their preferred partner for regulatory advice and support across multiple projects.
Mats Lundgren, CSO at Abera Bioscience, says:
“Abera Bioscience is an emerging vaccine company dedicated to developing groundbreaking vaccine candidates for mucosal administration. Our primary goal is to induce a robust mucosal immune response that can effectively block the transmission of infectious diseases, a critical need in global health. We have collaborated with RegSmart on several projects, and they are our preferred partner for regulatory support and advice. I am constantly impressed by the high-quality guidance and the efficient, flexible support provided by the RegSmart team.”
“As a small company, it is essential for us to work with partners who understand both the scientific challenges and the business aspects of vaccine development. RegSmart excels in both areas, offering expert advice and ensuring timely deliveries. It is always a pleasure to interact with the team, and their professional yet personal approach makes them more than just a consultancy, they are a trusted partner. For me, RegSmart is a key collaborator who adds real value and contributes to our continued success.”